ANTICOAGULATION MANAGEMENT IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: A SINGLE-CENTER REAL-WORLD EXPERIENCE (SIE 2026) - Oct 6, 2026 - Abstract #DP150; Pres time: Sep 22, 2026; 06:30 PM - 07:30 PM; Location: AREA POSTER; "All patients received CI therapy: ecul- izumab(N=2), ravulizumab(N=6), iptacopan (N=1), and ravulizumab plus danicopan (N=1)...Anticoagu- lant strategies included switch from warfarin to rivaroxaban after eight years, switch from long-term fondaparinux to re- duced-dose apixaban because of mild thrombocytopenia, and intermediate-dose low-molecular-weight heparin (LMWH)...However, anticoagulation management remains highly individualized, with platelet count representing a key determinant of treatment intensity and safety. In this co- hort, DOACs appeared feasible and safe during prolonged follow-up and may represent a practical option for selected PNH patients requiring secondary thromboprophylaxis."
Clinical • Real-world • Real-world evidence • Aplastic Anemia • Cardiovascular • Complement-mediated Rare Disorders • Hematological Disorders • Infectious Disease • Paroxysmal Nocturnal Hemoglobinuria • Rare Diseases • Thrombocytopenia • Thrombosis
|
|
S. Raso1; G. Camarda1; S. D'Angelo1; R. Di Maggio1; A. Giangreco1; R. Tomasello1; M. Napolitano1,2
|